Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, and its news flow reflects the progress and challenges of advancing a pipeline in oncology. Company updates frequently highlight developments in its lead programs, including BDC-3042, a first-in-class agonist antibody targeting dectin-2 on tumor-associated macrophages, and BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2.
On this page, readers can follow BOLT news related to clinical trial milestones, preclinical data presentations, and collaboration activities. Press releases have detailed Phase 1 dose-escalation results for BDC-3042 in patients with advanced solid tumors, including safety, pharmacokinetics, and early signs of anti-tumor activity. Other announcements describe the opening and conduct of the BDC-4182 Phase 1 study in gastric and gastroesophageal cancer, protocol updates such as the introduction of step-up dosing, and expectations for future clinical data readouts as disclosed by the company.
News items also cover preclinical Boltbody ISAC programs targeting CEA and PD-L1, with data presented at major scientific meetings like the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). These releases summarize findings such as complete tumor regressions in animal models, induction of immunological memory, and favorable toxicology profiles in non-human primates.
In addition, Bolt Biotherapeutics issues regular financial results and business updates, including quarterly and annual earnings releases, cash runway commentary, and information about restructuring actions intended to reduce operating expenses. Collaboration updates with partners such as Genmab and Toray, as well as participation in investor and scientific conferences, are also common topics. Investors and observers can use this news feed to track how Bolt Biotherapeutics’ clinical, preclinical, and corporate activities evolve over time.
Bolt Biotherapeutics (Nasdaq: BOLT) announced that CEO Randall C. Schatzman, Ph.D., will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:00 p.m. PT. The event includes a fireside chat and opportunities for investor meetings. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event. Bolt is focused on developing innovative immuno-oncology agents, particularly its lead candidate BDC-1001, targeting HER2-expressing solid tumors.
Bolt Biotherapeutics (Nasdaq: BOLT) announced three presentations at the 2021 SITC Annual Meeting in Washington, D.C., from Nov. 10-14. These presentations focus on assets in Bolt’s preclinical pipeline, featuring two immune-stimulating antibody conjugate (ISAC) candidates and an agonist antibody. The poster presentations will include:
- BDC-2034: CEA-targeting ISAC for solid tumors.
- Dectin-2: Aiming at tumor macrophage reprogramming.
- PD-L1-targeted ISAC: Enhancing anti-tumor efficacy in preclinical models.
Bolt Biotherapeutics (Nasdaq: BOLT) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate the combination of BDC-1001, a HER2-targeting immune-stimulating antibody conjugate, with Bristol's PD-1 inhibitor, Opdivo (nivolumab). The Phase 1/2 trial will explore safety and effectiveness in HER2-expressing solid tumors. Preliminary data presented at ASCO indicated promising results. Bristol will supply Opdivo for the trial, which is set to begin dose escalation later in 2021.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, has announced their participation in four virtual investor conferences this September. Key events include presentations at the Citi’s 16th Annual BioPharma Virtual Conference on Sept. 8, the Wells Fargo Virtual Healthcare Conference on Sept. 9, a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Sept. 13, and a presentation at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Sept. 30. Live and archived webcasts will be available on Bolt's website.
Bolt Biotherapeutics (BOLT) has entered into a collaboration with Innovent Biologics to develop three new anti-cancer therapeutic immune-stimulating antibody conjugates (ISACs). Innovent will pay an upfront fee of $5 million and handle development costs through clinical proof of concept. The partnership allows Innovent exclusive rights in Greater China while Bolt retains rights elsewhere. Potential future equity investments could reach $10 million, alongside milestone payments and royalties based on product development and commercialization.
Bolt Biotherapeutics (NASDAQ: BOLT) announced promising updates in its Phase 1/2 trial for BDC-1001 targeting HER2-expressing solid tumors, with data expected in 2H 2021. The company reported a robust cash position of $310.9 million as of June 30, 2021, which will fund operations through 2023. A collaboration with Genmab aims to develop bispecific ISACs for cancer treatment, securing an upfront payment of $10 million and potential future earnings of $285 million per program. R&D expenses rose to $19.7 million, while G&A expenses increased to $4.1 million in Q2 2021.
Bolt Biotherapeutics (BOLT) has showcased positive preliminary data from a Phase 1/2 clinical trial of BDC-1001 at the ASCO Annual Meeting. As of January 29, 2021, 20 patients treated with the HER2-targeting ISAC displayed tolerable safety with no serious adverse effects. Clinical activity included stable disease and a confirmed partial response in some patients. The trial aims to enroll up to 390 patients, with further results expected in H2 2021, including monotherapy and combination treatments.
Genmab and Bolt Biotherapeutics announced a collaboration aimed at developing novel cancer therapies using Genmab's antibody technologies and Bolt's immune-stimulating antibody conjugate (ISAC) platform. The partnership includes an upfront payment of USD 10 million and an equity investment of USD 15 million from Genmab. They plan to develop multiple bispecific ISAC candidates, with Genmab holding options to commercialize up to three candidates. Total potential milestone payments could reach USD 285 million per candidate, depending on successful development and commercialization.
Bolt Biotherapeutics reported a strong cash position of $302.9 million as of March 31, 2021, which is anticipated to support operations into 2023. The company successfully raised $264.5 million from its upsized IPO in February 2021. Bolt is progressing on its lead program, BDC-1001, with a Phase 1/2 trial expected to provide updates in the second half of 2021. In Q1 2021, R&D expenses rose to $14.1 million, while the loss from operations increased to $24.5 million. The company's strategic initiatives aim to enhance shareholder value through ongoing clinical trials and pipeline advancements.
Bolt Biotherapeutics (Nasdaq: BOLT) announced the ongoing Phase 1/2 study of its lead clinical candidate, BDC-1001, at the AACR Annual Meeting 2021. This first-in-class HER2-targeting immune-stimulating antibody conjugate is designed to convert cold tumors into hot ones, enhancing anti-tumor immune response. The study involves evaluating safety and efficacy in up to 390 patients with HER2-expressing tumors. Initial results showed promising signs of clinical activity and acceptable safety with no dose-limiting toxicities reported.